Loading
PERRIGO Co plc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Nov 2025.
PERRIGO Co plc: what insiders have been doing
Headquartered in Ireland, Ireland, PERRIGO Co plc belongs to the Healthcare & Pharma sector and traces its origins to 1887. Filings by its managers are published through SEC (Form 4). 16 insiders have disclosed 44 filings since 18 October 2025.
No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €92k, made by 1 insider. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 senior executive. Parker Geoffrey M. filed the largest purchase, €92k, on 14 November 2025.
With 44 filings in twelve months, the company is more active than the median of 19 filings across the 5,812 companies we follow on the same exchange. Our records for PERRIGO Co plc go back to 2016, with 25 purchases and 14 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 4.25 bn USD and net income of -1.43 bn USD, with a dividend of 1.16 USD per share.
The most recent open-market purchase was published on 14 November 2025, 338 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
198
Thresholds
n/a
Buy Volume
€4M
25 ops. · all time
Sell Volume
€10M
14 ops. · all time
Who traded when
BuySaleGeoffrey M. Parker4 buys
Abigail Lennox1 buy
Charles Atkinson1 buy
Eduardo Guarita Bezerra1 buy
Jeffrey B. Kindler1 sale
Patrick Lockwood-Taylor1 buy
+1 other insider
Since the insiders bought
- +7.2%Entry US$13.56 · Close at T+90 US$14.54
- -39.4%Entry US$22.55 · Close at T+365 US$13.66
- -38.6%Entry US$22.12 · Close at T+365 US$13.59
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,707 of 24,161 companies
29.6
score / 100
Value38
Quality22
FCF yld6.3%
Earn yld-62%
EV/EBITDA·
ROE-49%
Gross mgn35%
Net mgn-34%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$15.95
Analyst consensus
4 analysts2.40/5
US$14.00Target US$16.50(+3%)US$20.00
Income statement
RevenueUS$4.3B
Gross profitUS$1.5B35% margin
EBITDA-US$797.9M-19% margin
Net income-US$1.4B-41.9% margin
Valuation
PER (forward)6.7x
P/Book0.9x
Beta0.69
Balance sheet & cash
Market capUS$2.2B
Total debtUS$3.6B
Free Cash FlowUS$145.1M
Debt / Equity138%
Profitability & ownership
ROE-48.7%
ROA2.0%
% insiders0.4%
% institutions115.5%
Last declaration on 15 September 2026
Declarations198 total
1,263 shares@ US$13.660.0009% mcap0.9% of flowOrdinary SharesSEC:0001585364-26-000149:0
607 shares@ US$13.660.0004% mcap0.4% of flowOrdinary SharesSEC:0001585364-26-000149:1
1,263 shares@ US$13.660.0009% mcap0.7% of flowOrdinary SharesSEC:0001585364-26-000151:0
607 shares@ US$13.660.0004% mcap0.3% of flowOrdinary SharesSEC:0001585364-26-000151:1
7,701 shares@ US$14.340.0056% mcap30.4% of flowOrdinary SharesSEC:0001585364-26-000147:0
2,784 shares@ US$14.340.0020% mcap11.0% of flowOrdinary SharesSEC:0001585364-26-000147:1
737 shares@ US$10.520.0004% mcap3.6% of flowOrdinary SharesSEC:0001585364-26-000112:0
385 shares@ US$10.520.0002% mcap1.9% of flowOrdinary SharesSEC:0001585364-26-000112:1
15,660 shares@ US$10.520.0086% mcap58.8% of flowOrdinary SharesSEC:0001585364-26-000114:0
963 shares@ US$10.520.0005% mcap3.6% of flowOrdinary SharesSEC:0001585364-26-000114:3
8,175 shares@ US$10.520.0045% mcap30.7% of flowOrdinary SharesSEC:0001585364-26-000114:1
1,843 shares@ US$10.520.0010% mcap6.9% of flowOrdinary SharesSEC:0001585364-26-000114:2
976 sharesOrdinary SharesSEC:0001585364-26-000093:0
469 sharesOrdinary SharesSEC:0001585364-26-000093:1
6,690 shares@ US$10.830.0047% mcap62.8% of flowOrdinary SharesSEC:0001585364-26-000077:0
1,835 shares@ US$10.830.0013% mcap17.2% of flowOrdinary SharesSEC:0001585364-26-000077:1
2,867 shares@ US$10.830.0020% mcap8.6% of flowOrdinary SharesSEC:0001585364-26-000079:0
1,037 shares@ US$10.830.0007% mcap3.1% of flowOrdinary SharesSEC:0001585364-26-000079:1
9,175 shares@ US$10.830.0064% mcap4.7% of flowOrdinary SharesSEC:0001585364-26-000081:0
2,235 shares@ US$10.830.0016% mcap1.2% of flowOrdinary SharesSEC:0001585364-26-000081:1
3,507 shares@ US$10.840.0022% mcap6.7% of flowOrdinary SharesSEC:0001585364-26-000056:1
3,507 shares@ US$10.840.0022% mcap32.4% of flowOrdinary SharesSEC:0001585364-26-000050:1
5,122 shares@ US$10.840.0032% mcap3.5% of flowOrdinary SharesSEC:0001445728-26-000002:1
3,507 shares@ US$10.840.0022% mcap1.9% of flowOrdinary SharesSEC:0001585364-26-000052:1
7,305 shares@ US$10.840.0035% mcap3.1% of flowOrdinary SharesSEC:0001585364-26-000075:0
25 of 198 declarations
About PERRIGO Co plc
Perrigo Company plc (ticker: PRGO) is a U.S.-listed stock traded on the NYSE, making it relevant for investors following SEC Form 4 insider transactions and U.S. consumer-health equities. Although Perrigo is incorporated in Ireland and its corporate headquarters are in Dublin, its investor base, disclosure profile, and operating footprint are closely tied to the United States, where the company maintains a major manufacturing and commercial presence. The business traces its roots back to 1887, when Luther Perrigo began packaging and distributing patented medicines and household items for country stores. That heritage still shapes the company’s identity as a scale player in affordable, widely distributed self-care products. ([perrigo.com](https://www.perrigo.com/history-convenient-healthy-solutions?utm_source=openai))
Today, Perrigo is positioned as a leading provider of consumer self-care products and over-the-counter health and wellness solutions. Its portfolio spans OTC medicines, oral care, infant formula, women’s health, skincare, digestive health, smoking cessation, and related self-care categories. SEC filings show that Perrigo has historically organized its business around consumer self-care segments, and more recent reporting reflects a continuing push to align the company’s structure more tightly with its commercial operating model. This matters because Perrigo’s economics depend on breadth of category coverage, regulatory execution, and manufacturing scale across both private-label and branded products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001944048/000194404825000118/final2024annualreport.pdf?utm_source=openai))
Read moreShow less
Competitive positioning is one of Perrigo’s key strengths. The company has described itself as the largest U.S. manufacturer of OTC self-care products by volume, supported by 11 U.S. manufacturing facilities and a high domestic sourcing and production mix. That scale gives Perrigo leverage with retailers, helps protect supply reliability, and supports its store-brand leadership in categories where price, availability, and trust are critical. ([investor.perrigo.com](https://investor.perrigo.com/2025-05-07-Perrigo-Reports-First-Quarter-2025-Financial-Results-From-Continuing-Operations?utm_source=openai))
Its product set includes everyday essentials rather than prescription drugs: cough, cold and allergy treatments; pain care; digestive health; oral care; baby care; women’s health; and other self-care categories. Perrigo also has exposure to infant nutrition, which has been an operational focus in recent periods. A notable consumer-facing milestone was the U.S. launch of Opill®, the first over-the-counter oral contraceptive in the country, rolled out through a large retail network. This launch highlighted Perrigo’s ability to combine scientific, regulatory, and commercial capabilities in a high-visibility category. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1585364/000158536424000066/cy24q1ex991pressrelease.htm?utm_source=openai))
Recent developments suggest a company in transition rather than in a static defensive profile. In 2025, Perrigo announced strategic reviews of its infant formula and oral care businesses and signed an agreement to divest its Dermacosmetics business; that transaction was completed in 2026. Management has also emphasized a simplification agenda, a new operating model, and cost-savings initiatives aimed at stabilizing performance and improving long-term margins. For investors, PRGO combines defensive consumer-health exposure with a meaningful portfolio-repositioning story. ([investor.perrigo.com](https://investor.perrigo.com/2025-11-05-Perrigo-to-Conduct-Strategic-Review-of-its-Infant-Formula-Business?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
